Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABVX NASDAQ:ARQT NASDAQ:CYTK NASDAQ:PRAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$130.10-1.9%$118.43$5.69▼$148.83$10.37B0.691.11 million shs1.05 million shsARQTArcutis Biotherapeutics$21.36-0.5%$22.57$12.72▼$31.77$2.68B1.521.50 million shs629,021 shsCYTKCytokinetics$73.68-4.0%$68.95$30.55▼$80.20$9.15B0.422.19 million shs977,430 shsPRAXPraxis Precision Medicines$341.74-2.4%$326.47$37.19▼$366.52$9.50B2.71442,606 shs125,080 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax0.00%+8.72%+12.99%+17.26%+2,110.50%ARQTArcutis Biotherapeutics0.00%+2.88%-7.58%-13.33%+63.94%CYTKCytokinetics0.00%-0.23%+19.99%+24.96%+148.58%PRAXPraxis Precision Medicines0.00%+1.87%+9.77%+5.86%+807.13%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$130.10-1.9%$118.43$5.69▼$148.83$10.37B0.691.11 million shs1.05 million shsARQTArcutis Biotherapeutics$21.36-0.5%$22.57$12.72▼$31.77$2.68B1.521.50 million shs629,021 shsCYTKCytokinetics$73.68-4.0%$68.95$30.55▼$80.20$9.15B0.422.19 million shs977,430 shsPRAXPraxis Precision Medicines$341.74-2.4%$326.47$37.19▼$366.52$9.50B2.71442,606 shs125,080 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax0.00%+8.72%+12.99%+17.26%+2,110.50%ARQTArcutis Biotherapeutics0.00%+2.88%-7.58%-13.33%+63.94%CYTKCytokinetics0.00%-0.23%+19.99%+24.96%+148.58%PRAXPraxis Precision Medicines0.00%+1.87%+9.77%+5.86%+807.13%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABVXAbivax 2.93Moderate Buy$137.155.73% UpsideARQTArcutis Biotherapeutics 2.50Moderate Buy$34.0058.40% UpsideCYTKCytokinetics 2.86Moderate Buy$99.3034.34% UpsidePRAXPraxis Precision Medicines 2.95Moderate Buy$592.6774.67% UpsideCurrent Analyst Ratings BreakdownLatest ARQT, ABVX, PRAX, and CYTK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2026PRAXPraxis Precision Medicines Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/26/2026ABVXAbivax CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform5/26/2026ABVXAbivax Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$131.005/26/2026PRAXPraxis Precision Medicines HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$1,245.005/20/2026PRAXPraxis Precision Medicines BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$843.005/18/2026CYTKCytokinetics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform ➝ Buy$99.005/18/2026CYTKCytokinetics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeOutperform ➝ Strong-Buy5/13/2026PRAXPraxis Precision Medicines Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$700.00 ➝ $715.005/12/2026CYTKCytokinetics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$92.00 ➝ $97.005/11/2026CYTKCytokinetics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$136.00 ➝ $140.005/8/2026PRAXPraxis Precision Medicines Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$420.00(Data available from 6/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABVXAbivaxN/AN/AN/AN/A$6.57 per shareN/AARQTArcutis Biotherapeutics$376.07M7.14N/AN/A$1.55 per share13.85CYTKCytokinetics$88.04M104.47N/AN/A($5.39) per share-13.71PRAXPraxis Precision Medicines$8.55M1,106.44N/AN/A$34.85 per share9.74Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABVXAbivax-$380.27M-$5.21N/AN/AN/AN/A-99.02%-70.26%N/AARQTArcutis Biotherapeutics-$16.14M-$0.03N/A22.36N/A-0.57%-1.41%-0.59%8/5/2026 (Estimated)CYTKCytokinetics-$784.96M-$6.84N/AN/AN/A-784.02%N/A-52.86%8/6/2026 (Estimated)PRAXPraxis Precision Medicines-$303.27M-$13.37N/AN/AN/AN/A-43.02%-40.22%8/3/2026 (Estimated)Latest ARQT, ABVX, PRAX, and CYTK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/22/2026Q1 2026ABVXAbivax-$0.9359-$0.71+$0.2259-$0.71$0.40 million$1.56 million5/7/2026Q1 2026PRAXPraxis Precision Medicines-$3.58-$3.20+$0.38-$3.20$0.10 millionN/A5/6/2026Q1 2026ARQTArcutis Biotherapeutics-$0.02-$0.09-$0.07-$0.09$103.68 million$105.40 million5/5/2026Q1 2026CYTKCytokinetics-$1.67-$1.67N/A-$1.67$8.52 million$19.36 million3/23/2026Q4 2025ABVXAbivax-$2.24-$1.20+$1.04-$1.20$1.80 million$0.52 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABVXAbivaxN/AN/AN/AN/AN/AARQTArcutis BiotherapeuticsN/AN/AN/AN/AN/ACYTKCytokineticsN/AN/AN/AN/AN/APRAXPraxis Precision MedicinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABVXAbivaxN/A8.258.25ARQTArcutis Biotherapeutics0.542.682.46CYTKCytokineticsN/A4.214.21PRAXPraxis Precision MedicinesN/A15.8815.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABVXAbivax47.91%ARQTArcutis BiotherapeuticsN/ACYTKCytokineticsN/APRAXPraxis Precision Medicines67.84%Insider OwnershipCompanyInsider OwnershipABVXAbivaxN/AARQTArcutis Biotherapeutics9.40%CYTKCytokinetics2.60%PRAXPraxis Precision Medicines2.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABVXAbivax6179.69 millionN/ANot OptionableARQTArcutis Biotherapeutics150125.08 million113.33 millionOptionableCYTKCytokinetics250124.43 million121.20 millionOptionablePRAXPraxis Precision Medicines11027.88 million27.13 millionOptionableARQT, ABVX, PRAX, and CYTK HeadlinesRecent News About These CompaniesAnalysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX) and Eli Lilly & Co (LLY)May 28, 2026 | theglobeandmail.comPraxis Precision Medicines' (PRAX) Buy Rating Reaffirmed at BTIG ResearchMay 21, 2026 | americanbankingnews.comIs FDA NDA Progress Amid Wider Losses Altering The Investment Case For Praxis Precision Medicines (PRAX)?May 18, 2026 | finance.yahoo.comPraxis Precision Medicines (NASDAQ:PRAX) Given New $715.00 Price Target at Truist FinancialMay 13, 2026 | marketbeat.comPraxis Precision Medicines, Inc. (PRAX) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks TranscriptMay 12, 2026 | seekingalpha.comHC Wainwright Issues Pessimistic Outlook for PRAX EarningsMay 12, 2026 | marketbeat.comLifesci Capital Brokers Lower Earnings Estimates for PRAXMay 12, 2026 | marketbeat.comPraxis Precision Medicines Maps High-Stakes Launch PathMay 11, 2026 | tipranks.comWedbush Maintained an Underperform Rating on Praxis Precision Medicines, Inc. (PRAX)May 11, 2026 | insidermonkey.comUBS Group AG Sells 7,612 Shares of Praxis Precision Medicines, Inc. $PRAXMay 11, 2026 | marketbeat.comState of New Jersey Common Pension Fund D Acquires New Position in Praxis Precision Medicines, Inc. $PRAXMay 11, 2026 | marketbeat.comResearch Analysts Issue Forecasts for PRAX FY2030 EarningsMay 11, 2026 | marketbeat.comPraxis Precision Medicines, Inc. (PRAX) Q1 2026 Earnings Call TranscriptMay 9, 2026 | seekingalpha.comAnalysts Are Bullish on These Healthcare Stocks: Praxis Precision Medicines (PRAX), NewAmsterdam Pharma Company (NAMS)May 8, 2026 | theglobeandmail.comPraxis Precision Medicines Q1 Earnings Call HighlightsMay 8, 2026 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Price Target Raised to $166.00May 8, 2026 | marketbeat.comBTIG Research Reaffirms Buy Rating for Praxis Precision Medicines (NASDAQ:PRAX)May 8, 2026 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Issues Earnings ResultsMay 7, 2026 | marketbeat.comPraxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial ResultsMay 7, 2026 | finanznachrichten.dePraxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial ResultsMay 7, 2026 | globenewswire.comStrs Ohio Invests $943,000 in Praxis Precision Medicines, Inc. $PRAXMay 7, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARQT, ABVX, PRAX, and CYTK Company DescriptionsAbivax NASDAQ:ABVX$130.10 -2.54 (-1.91%) As of 02:51 PM Eastern This is a fair market value price provided by Massive. Learn more.ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.Arcutis Biotherapeutics NASDAQ:ARQT$21.36 -0.10 (-0.48%) As of 02:52 PM Eastern This is a fair market value price provided by Massive. Learn more.Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.Cytokinetics NASDAQ:CYTK$73.68 -3.09 (-4.02%) As of 02:51 PM Eastern This is a fair market value price provided by Massive. Learn more.Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.Praxis Precision Medicines NASDAQ:PRAX$341.74 -8.23 (-2.35%) As of 02:52 PM Eastern This is a fair market value price provided by Massive. Learn more.Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Braze Blazes Ahead on Q1 2027 Earnings Beat, Raised Guidance MarketBeat Week in Review – 05/25 - 05/29 Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17% What Exactly Is Agentic AI, and Why Are Some Stocks Blowing Up Because of It? Costco’s Strong Quarter Still Leaves Investors With a Valuation Problem SanDisk's Stock and Short Interest Both at Record Highs —Do the Bears Know Something? MongoDB's AI Advantage Is Starting to Show Up in Results 3 Ways to Play the Data Center Land Grab Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
